BRISTOL-MYERS SQUIBB COMPANY Bank Overdrafts
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Bank Overdrafts of $176.00 million as of 2017-12-31, per its 10-K filed 2018-02-13.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current › Short-Term Debt
us-gaap:BankOverdrafts · last filed 2018-02-13
- 2017-12-31: Bank Overdrafts $176.00M.
- 2016-12-31: Bank Overdrafts $134.00M; Bank Overdrafts as first filed $243.00M.
- 2015-12-31: Bank Overdrafts $139.00M.
- 2013-12-31: Bank Overdrafts $359.00M.
| Period end | Bank Overdrafts | Bank Overdrafts as first filed |
|---|---|---|
| 2017-12-31 | $176.00M 10-K · filed 2018-02-13 | |
| 2016-12-31 | $134.00M 10-K · filed 2018-02-13 | $243.00M 10-K · filed 2017-02-21 |
| 2015-12-31 | $139.00M 10-K · filed 2017-02-21 | |
| 2013-12-31 | $359.00M 10-K · filed 2014-02-14 | |
| 2012-12-31 | $162.00M 10-K · filed 2014-02-14 | |
| 2011-12-31 | $113.00M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |